Fish Oil Triglycerides
drugOn this page
Also known as Omegaven
Summary
Fish Oil Triglycerides (CHEMBL4297535) is an approved unknown; indicated across 10 conditions including cholestasis and carcinoma.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Unknown
- Indications: 10 conditions
- Clinical trials: 42
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297535 |
| Name | Fish Oil Triglycerides |
| Type | Unknown |
| Max phase | 4 |
Also known as: Fish oil triglycerides, Omegaven, FISH OIL TRIGLYCERIDES
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
10 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| cholestasis | 4 | MONDO:0001751 | MONDO:0001751 |
| carcinoma | 3 | MONDO:0004993 | EFO:0000313 |
| rheumatoid arthritis | 3 | MONDO:0008383 | EFO:0000685 |
| acute myeloid leukemia | 2 | MONDO:0018874 | EFO:0000222 |
| liver disorder | 2 | MONDO:0005154 | EFO:0001421 |
| retinopathy of prematurity | 2 | MONDO:0006952 | EFO:1001158 |
| esophageal atresia | 2 | MONDO:0001044 | HP:0002032 |
| hepatitis | 2 | MONDO:0002251 | HP:0012115 |
| ventricular tachycardia | 1 | MONDO:0005477 | EFO:0005306 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 42.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 17 |
| PHASE2 | 9 |
| PHASE4 | 7 |
| PHASE2/PHASE3 | 3 |
| PHASE3 | 2 |
| PHASE1/PHASE2 | 2 |
| PHASE1 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00172198 | PHASE4 | UNKNOWN | Omegaven (w-3 Fish Oil) Supplemented Parenteral Nutrition in Subjects of SICU. |
| NCT00558155 | PHASE4 | COMPLETED | The Impact of Immunostimulating Nutrition on the Outcome of Surgery |
| NCT00732849 | PHASE4 | COMPLETED | The Impact of the Type and Route of Nutritional Support on Infectious Complications After Upper Gastrointestinal Surgery |
| NCT00862446 | PHASE4 | COMPLETED | Use of Omega-3 Fat Emulsion (Omegaven) in Infants With Parenteral Nutrition Associated Liver Disease |
| NCT02231203 | PHASE4 | COMPLETED | Effect of Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function |
| NCT02349594 | PHASE4 | COMPLETED | Immune Modulation by Parenteral Fish Oil in Patients With Crohn’s Disease |
| NCT03149653 | PHASE4 | COMPLETED | Crossover Study on the Effect of Omegaven in Combination With Different Lipid Emulsions in Home Parenteral Nutrition |
| NCT00412256 | PHASE3 | COMPLETED | Omegaven in Patients With Rheumatoid Arthritis (ORA-Trial) |
| NCT01247012 | PHASE2/PHASE3 | UNKNOWN | Minimization of IntraLipid Versus Omegaven |
| NCT02370251 | PHASE2/PHASE3 | COMPLETED | Compassionate Use of Omegaven in Children |
| NCT03662282 | PHASE3 | COMPLETED | Omegaven as Alternative Parenteral Fat Nutrition |
| NCT04697888 | PHASE2/PHASE3 | COMPLETED | Use of Omegaven for Treatment With Parenteral Nutrition Associated Liver Disease |
| NCT00533078 | PHASE2 | COMPLETED | Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies |
| NCT00534300 | PHASE1/PHASE2 | COMPLETED | Intravenous n-3 Fatty Acids and Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillator (ICD)-Pacemaker |
| NCT00816348 | PHASE2 | TERMINATED | Compassionate Use of Omegaven IV Fat Emulsion |
| NCT00969332 | PHASE2 | TERMINATED | A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease |
| NCT01325584 | PHASE2 | TERMINATED | Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Hepatic Injury |
| NCT01601652 | PHASE1/PHASE2 | COMPLETED | Compassionate Use of an Intravenous Fish Oil Emulsion in Infants With Cholestasis |
| NCT01739517 | PHASE2 | UNKNOWN | Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease |
| NCT01870791 | PHASE2 | TERMINATED | Study of Additive Omega-3 Fish Oil to Palliative Chemotherapy to Treat Oesophagogastric Cancer |
| NCT01999413 | PHASE2 | COMPLETED | Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients |
| NCT02486042 | PHASE2 | COMPLETED | Omega-3 Long Chain Polyunsaturated Fatty Acid (LCPUFA) Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity |
| NCT03127345 | PHASE2 | WITHDRAWN | Omega 3 Fatty Acid Treatment for Pediatric Musculoskeletal Health |
| NCT00512629 | PHASE1 | COMPLETED | Cholestasis Prevention: Efficacy of IV Fish Oil |
| NCT02512718 | PHASE1 | COMPLETED | Safety and Tolerability of Intravenous Fish Oil Lipid Emulsion in Children Undergoing Hematopoietic Cell Transplantation |
| NCT00738101 | Not specified | COMPLETED | Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants |
| NCT01173159 | Not specified | COMPLETED | Compassionate Use of Omegaven to Reverse Parenteral Nutrition Induced Cholestasis |
| NCT01284049 | Not specified | COMPLETED | Evaluation of OMEGAVEN 10%® (n-3 EFA Lipid Emulsion) in Home Parenteral Nutrition-associated Liver Disease |
| NCT01297933 | Not specified | APPROVED_FOR_MARKETING | Compassionate Use of Omegaven for Pediatric Patients With Parenteral Nutrition Associated Liver Disease |
| NCT01861834 | Not specified | APPROVED_FOR_MARKETING | Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage |
| NCT02010034 | Not specified | COMPLETED | Compassionate Use of Omegaven in the Treatment of Parenteral Nutrition Induced Hepatic Injury |
| NCT02121769 | Not specified | NO_LONGER_AVAILABLE | Omegaven Expanded Access Protocol |
| NCT02148146 | Not specified | NO_LONGER_AVAILABLE | Use of Omega 3 Oil Emulsion for Parenteral Nutrition Associated Cholestasis |
| NCT02328768 | Not specified | APPROVED_FOR_MARKETING | Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children |
| NCT02334293 | Not specified | UNKNOWN | Omegaven® as Parenteral Nutrition |
| NCT02534077 | Not specified | APPROVED_FOR_MARKETING | Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants |
| NCT02778698 | Not specified | APPROVED_FOR_MARKETING | Compassionate Use of Omegaven |
| NCT02780193 | Not specified | APPROVED_FOR_MARKETING | Intravenous Fish Oils in the Treatment of Parenteral Nutrition Liver Injury |
| NCT02925520 | Not specified | NO_LONGER_AVAILABLE | Expanded Access Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Liver Injury in Children |
| NCT03072667 | Not specified | APPROVED_FOR_MARKETING | Omegaven for Compassionate Use in the Treatment of Parenteral Nutrition-Associated Liver Disease |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: cholestasis, carcinoma, rheumatoid arthritis